Zynex shares are up ~100x since late 2016 as retail investors buy into a story of rapid revenue and earnings growth. However, we believe Zynex is dependent on an abusive pricing strategy - reselling ...

Zynex, Inc. (NASDAQ:ZYXI) just released its latest full-year report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst estimates at ...

Zynex Inc. ZYXI recently announced the Food and Drug Administration (“FDA”) clearance of its new TensWave device, which aligns perfectly with Zynex’s commitment to providing comprehensive pain ...

Analysts are estimating that Zynex will report an earnings per share (EPS) of $-0.16. Anticipation surrounds Zynex's ...

Zynex, Inc.'s Q3 2025 report details new leadership, ongoing debt restructuring, and compliance focus amid revenue and liquidity challenges.

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson ...

Zynex Inc (ZYXI) has disclosed a new risk, in the Litigation & Legal Liabilities category. Zynex Inc. faces significant business risks due to ...

Q3 2025 Earnings Call Transcript November 18, 2025 Operator: Excuse me, ladies and gentlemen. This is the operator speaking.

Shares of pain-management equipment specialist Zynex (NASDAQ: ZYXI) were falling in Friday trading, down as much as 23.4%, before recovering to a 13.4% decline as of 3:25 p.m. EDT. The medical ...

LITTLETON, Colo.--(BUSINESS WIRE)-- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces plans to ...

Zynex Inc's (NASDAQ:ZYXI) board of directors approved a program to repurchase up to $20.0 million. The program will commence on November 1, 2023, and is scheduled to terminate earlier than November 1, ...